LungLife AI, Inc.
(the "Company" or
"LungLife")
Publication of Annual Report
and Accounts & Notice of AGM
LungLife AI (AIM: LLAI), a developer
of clinical diagnostic solutions for lung cancer, announces that the Annual Report
and Accounts, Notice of Annual General Meeting
("AGM"), Form of Direction and associated Form of Proxy are now available on the
Company's website and will be posted to those shareholders who have
opted out of electronic communications
today.
The documents are available here:
lunglifeai.com/investors/financial-information-documents-presentations/
The Company's AGM will be
held at 4:00 P.M. (BST) on 5 June 2024, at Investec
Bank plc, 30 Gresham Street, London, EC2V 7QP. The Board will make
arrangements for shareholders to listen to proceedings remotely
should they wish to do so. The Company will announce details of how
to listen to the meeting remotely and any other significant changes
to the meeting arrangements via RNS and on LungLife's website
at investors.lunglifeai.com/
Shareholders are strongly encouraged to vote by
proxy, whether or not you plan to attend the Company's Annual
General Meeting in person. You may register your votes on the
resolutions of the Annual General Meeting by completing and
returning the proxy form that accompanies this Notice in accordance
with the instructions printed on the proxy form.
If shareholders' holding of Common Shares is by
way of dematerialised depository interests representing underlying
Common Shares ("Depository Interests"), they can vote through the
CREST system or by returning a Form of Instruction to the
Depositary. Further instructions are set out in the Notes to the
Notice of Annual General Meeting.
The resolutions to be proposed at the Annual
General Meeting are summarised in the Notice of AGM.
The results of voting on the resolutions will
be announced via a regulatory information service and posted on the
Company's website as soon as practicably possible after the
AGM.
For further
information please contact:
|
LungLife AI,
Inc.
|
www.lunglifeai.com
|
|
Paul Pagano, CEO
|
Via Walbrook PR
|
|
David Anderson, CFO
|
|
|
|
|
|
Investec Bank plc (Nominated Adviser &
Joint
Broker)
|
Tel: +44 (0)20 7597
5970
|
|
Virginia Bull / Cameron MacRitchie / Lydia
Zychowska
|
|
|
Goodbody
(Joint Broker)
Tom Nicholson / Cameron Duncan
|
Tel: +44 (0) 20 3841
6202
|
|
|
|
|
Walbrook PR Limited
|
Tel: +44 (0)20 7933
8780 or LungLifeAI@walbrookpr.com
|
|
Stephanie Cuthbert / Alice Woodings
/ Phillip Marriage
|
Mob: 07980
541 893 / 07407 804 654 / 07867 984 082
|
About LungLife
LungLife AI is a developer of
clinical diagnostic solutions designed to make a significant impact
in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the
Company's LungLB® test is designed to deliver additional
information to clinicians who are evaluating indeterminate lung
nodules. For more information visit
www.lunglifeai.com
Our Purpose is to be a driving force in the
early detection to lung cancer. Our Vision is to invert the
20:80 ratio such that in years to come at least 80% of lung cancer
is detected early.